News | Stents Carotid | June 17, 2015

New Research Explores "Myth" of Restenosis After Carotid Angioplasty and Stenting

Restenosis rates vary but are higher for patients with history of carotid endarterectomy or neck irradiation

June 17, 2015 - Karam Moon, M.D., winner of the DePuy Synthes Cerebrovascular Section Resident/Fellow Award, presented his research, The Myth of Restenosis after Carotid Angioplasy and Stenting, at the American Association of Neurological Surgeons (AANS) annual scientific meeting in May.

Carotid endarterectomy and stenting was shown to have similar safety and efficacy in the Stenting versus Endarterectomy for Treatment of Carotid-Artery Stenosis Trial (CREST). Restenosis rates after endovascular treatment are highly variable in the literature and risk factors for this pathology are poorly understood.

The study's authors reviewed all patients undergoing carotid artery stenting (CAS) between 1995 and 2010. Symptomatic and asymptomatic patients were selected based on North American Symptomatic Carotid Endarterectomy Trial (NASCET) and Asymptomatic Carotid Atherosclerosis Study (ACAS) criteria. Risk factors, indications, rates of technical success, intraoperative and perioperative complications, restenosis (>50 percent) rate and clinical outcomes were evaluated.

A total of 156 patients met inclusion criteria, but 35 were lost to follow-up, leaving 121 patients with 133 vessels treated. Ninety-one (68.4 percent) lesions were symptomatic. Indications for stent placement included patients who were poor surgical candidates, prior endarterectomy, prior radiation, study randomization, acute occlusions, tandem stenosis, high bifurcation and contralateral laryngeal nerve palsy.

Procedures were technically successful in all but one case. Intraoperative and peri-operative stroke occurred in four patients (3 percent). Mean follow-up was 38 months (range one to 204 months). Patients with a prior history of carotid endarterectomy or neck irradiation (hostile-neck) (n=57) comprised 42.9 percent of all vessels treated and were responsible for 15 of 23 restenosis cases, resulting in a significantly higher restenosis rate when compared with primary atherosclerosis lesions (26.3 percent vs. 10.5 percent, P=.017). Five patients (3.8 percent) with restenosis were symptomatic, four of whom were part of the hostile-neck group.

Rates of in-stent restenosis after carotid angioplasty and stenting are low, but differ between patients with atherosclerotic and hostile-neck etiologies. In this large modern series of carotid artery stenting at a high-volume institution, nearly half of lesions treated were hostile-neck carotids, a cohort that is at higher risk for substantial radiographic and symptomatic restenosis. Counseling for patients undergoing CAS should reflect the differences between these distinct pathologies.

For more information: www.aans.org

Related Content

Open Heart Surgery Outperforms Stents in Patients With Multivessel Disease
News | Cardiovascular Surgery | May 03, 2019
Coronary artery bypass grafting (CABG) surgery may be the best treatment option for most patients with more than one...
SherpaPak Cardiac Transport System Cleared for Pediatric and Small Donor Hearts
Technology | Cardiovascular Surgery | February 01, 2019
Paragonix Technologies Inc. recently received clearance from the U.S. Food and Drug Administration (FDA) for a design...
Transplanting Pig Hearts Into Humans One Step Closer. A pig heart, shown here, is very similar in size and anatomy to a human heart. For this reason, pigs are used extensively in pre-clinical animal testing for new implantable cardiovascular devices. If pig hearts could be used for human transplantation, it would greatly alleviate shortages of donor human hearts.

A pig heart, shown here, is very similar in size and anatomy to a human heart. For this reason, pigs are used extensively in pre-clinical animal testing for new implantable cardiovascular devices. If pig hearts could be used for human transplantation, it would greatly alleviate shortages of donor human hearts.

News | Cardiovascular Surgery | December 11, 2018
The scientific journal Nature recently published an article from Munich University Hospital which describes the long-...
Bilateral Artery Use Does Not Improve 10-Year CABG Outcomes
News | Cardiovascular Surgery | September 06, 2018
While it is firmly established that the use of one internal thoracic artery can improve life expectancy in coronary...
Mandatory Public Coronary Artery Bypass Grafting Reporting Associated With Better Patient Outcomes
News | Cardiovascular Surgery | April 30, 2018
Mandatory public reporting of coronary artery bypass grafting (CABG) results in Massachusetts was associated with...
Gecko Biomedical Receives CE Mark Approval for Setalum Sealant
News | Cardiovascular Surgery | September 19, 2017
Gecko Biomedical announced it has received CE Mark approval for its Setalum Sealant, allowing the company to market its...
ClearFlow Inc. Announces Positive U.S. Clinical Trial Results
News | Cardiovascular Surgery | September 08, 2017
September 8, 2017 — ClearFlow Inc.
Videos | Cardiovascular Surgery | July 19, 2017
This video educational session, provided in partnership with the American Society of Echocardiography (ASE), is title
Intensive Glycemic Control Program Produces Significant Per-Patient Cost Savings for CABG Surgery
News | Cardiovascular Surgery | May 25, 2017
A new study from Emory University observed a near-20 percent reduction in perioperative complications, a 1.2-day...
Overlay Init